- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:diseases:cfs [07.06.2019] – [Research] sallieq | home:diseases:cfs [01.18.2020] – [Chronic fatigue syndrome (myalgic encephalomyelitis)] sallieq | ||
|---|---|---|---|
| Line 1: | Line 1: | ||
| ====== Chronic fatigue syndrome (myalgic encephalomyelitis) ====== | ====== Chronic fatigue syndrome (myalgic encephalomyelitis) ====== | ||
| - | <relatedarticle> [[home: | + | <relatedarticles> [[home: |
| ===== Introduction ===== | ===== Introduction ===== | ||
| Line 80: | Line 80: | ||
| Patients with CFS showed abnormalities in 20 metabolic pathways. (({{pubmed> | Patients with CFS showed abnormalities in 20 metabolic pathways. (({{pubmed> | ||
| - | [[http:// | + | |
| =====Symptoms===== | =====Symptoms===== | ||
| Line 155: | Line 155: | ||
| In October 2009, we reported the first direct isolation of infectious xenotropic murine leukemia virus-related virus (XMRV). In that study, we used a combination of biological amplification and molecular enhancement techniques to detect XMRV in more than 75% of 101 patients with chronic fatigue syndrome (CFS).(({{pubmed> | In October 2009, we reported the first direct isolation of infectious xenotropic murine leukemia virus-related virus (XMRV). In that study, we used a combination of biological amplification and molecular enhancement techniques to detect XMRV in more than 75% of 101 patients with chronic fatigue syndrome (CFS).(({{pubmed> | ||
| + | [[http:// | ||
| ===== Impairment of immune function ===== | ===== Impairment of immune function ===== | ||
home/diseases/cfs.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.